Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group

[1]  R. Ladenstein,et al.  Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials , 2022, Cancers.

[2]  G. Schreier,et al.  Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience. , 2020, European journal of cancer.

[3]  N. Cheung,et al.  Reduced‐dose craniospinal irradiation for central nervous system relapsed neuroblastoma , 2020, Pediatric blood & cancer.

[4]  F. Berthold,et al.  Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. , 2019, JCO precision oncology.

[5]  Ruth Ladenstein,et al.  Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[6]  V. Čurin Šerbec,et al.  Targeting Malignant Brain Tumors with Antibodies , 2017, Front. Immunol..

[7]  C. Lynch,et al.  Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States , 2017, Pediatric hematology and oncology.

[8]  F. Berthold,et al.  Neuroblastoma metastatic to the central nervous system: Survival analyses from the German Childhood Cancer Registry and the literature. , 2017 .

[9]  Günter Schreier,et al.  Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  G. Tonini.  Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis? , 2017, BMC Cancer.

[11]  G. Tonini.  Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis? , 2017, BMC Cancer.

[12]  Peng-Fei Li,et al.  Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment , 2015, Chinese journal of cancer.

[13]  A. Jenkner,et al.  Local control in metastatic neuroblastoma in children over 1 year of age , 2015, BMC Cancer.

[14]  A. Jenkner,et al.  Local control in metastatic neuroblastoma in children over 1 year of age , 2015, BMC Cancer.

[15]  T. Tuschl,et al.  Deep MicroRNA sequencing reveals downregulation of miR‐29a in neuroblastoma central nervous system metastasis , 2014, Genes, chromosomes & cancer.

[16]  Irina Ostrovnaya,et al.  Recurrent pre‐existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases , 2013, Genes, chromosomes & cancer.

[17]  I. Ostrovnaya,et al.  Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Miyajima,et al.  Unexpected intraparenchymal hematoma caused by brain metastasis in a patient with neuroblastoma: case report. , 2011, Neurologia medico-chirurgica.

[19]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Berthold,et al.  Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials , 2011, Pediatric blood & cancer.

[21]  F. Berthold,et al.  Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy , 2011, BMC Cancer.

[22]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[23]  J. Humm,et al.  Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma , 2010, Journal of Neuro-Oncology.

[24]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[25]  K. Kramer,et al.  Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system , 2006, Bone Marrow Transplantation.

[26]  F. Berthold,et al.  Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. , 2005, The Lancet. Oncology.

[27]  J. Barker,et al.  Brain metastasis in children with sarcoma, neuroblastoma, and Wilms' tumor. , 2003, International journal of radiation oncology, biology, physics.

[28]  H. Brisse,et al.  Central nervous system metastases in neuroblastoma , 2003, Cancer.

[29]  G. Heller,et al.  Neuroblastoma metastatic to the central nervous system , 2001, Cancer.

[30]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[31]  S. Palasis,et al.  Central nervous system relapse following bone marrow transplantation in stage IV neuroblastoma. , 1999, Pediatric hematology and oncology.

[32]  D. Stram,et al.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. , 1999, Journal of pediatric hematology/oncology.

[33]  C. Fitz,et al.  Recognition of central nervous system metastases in children with metastatic primary extracranial neuroblastoma. , 1997, Pediatric hematology and oncology.

[34]  M. Fukuzawa,et al.  Evaluation of patients with advanced neuroblastoma surviving more than 5 years after initiation of an intensive Japanese protocol: a report from the Study Group of Japan for Treatment of Advanced Neuroblastoma. , 1996, Medical and pediatric oncology.

[35]  A. Navajas,et al.  Secondary central nervous system metastases in children with neuroblastoma. , 1996, Medical and pediatric oncology.

[36]  W. Pao,et al.  Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging , 1991, Cancer.

[37]  F. Graus,et al.  Brain metastases in children. , 1983, The Journal of pediatrics.

[38]  R. Vannucci,et al.  Cerebral metastatic disease in childhood , 1974, Neurology.

[39]  R. Kebudi,et al.  Brain metastasis in pediatric extracranial solid tumors: survey and literature review , 2004, Journal of Neuro-Oncology.

[40]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..